Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 26;11:186. doi: 10.1038/s41398-021-01303-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Immobility time in tail suspension test (TST) is reduced 3 days after daily administration of bpV. b, c Immobility time in TST and force swimming test is reduced 3 weeks after daily administration of bpV. d, e. Time spent in the open arm is increased in the elevated plus-maze test (d) and latency to eating food is reduced in the novelty suppressed feeding test (e) 3 weeks after daily administration of bpV. f, g Three-week systemic administration of bpV upregulates pAkt, pmTOR1, PSD-95, synapsinI, Arc, and p4EBP1 levels with no changes in PTEN, Akt, or mTOR1 in midbrain tissue containing the dorsal raphe nucleus. h, i Double immunostaining of TPH2 and pAkt shows the elevation of pAkt in 5-HT neurons in the DRN of bpV-treated mice. All the data are presented as the mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001. Numbers of animal used are indicated.